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CC BY-NC-ND license (http://creativeBackground/purpose: Although prophylactic antibiotics have been recommended for cirrhotic
patients with upper gastrointestinal bleeding, the duration of its use remains an inconclusive
issue. We designed this study to investigate the duration of antibiotic prophylaxis for cirrhotic
patients with acute esophageal variceal bleeding.
Methods: We enrolled those patients suffering from acute esophageal variceal bleeding and
receiving band ligation. They were randomly allocated to two groups to receive prophylactic
antibiotics; Group I: receiving intravenous ceftriaxone 500 mg every 12 hours for 3 days, and
Group II: same regimen for 7 days. We used rebleeding rate within 14 days as the primary
end point and also evaluated the survival rate within 28 days and the amount of transfusion
during admission.
Results: There were 38 patients in Group I and 33 patients in Group II that completed the study
course for analysis. Overall, there was no significant difference in the baseline characteristics
between these two groups. There were three patients both in Group I and Group II who devel-
oped rebleeding within 14 days (8% vs. 9%, p > 0.99). There was also no difference between
Group I and Group II in transfusion amount (2.71  2.84 units vs. 3.18  4.07, p Z 0.839)
and survival rate in 28 days (100 vs. 97%, p Z 0.465).
Conclusion: Our small scale study demonstrated that there was no difference in the rebleeding
rate between 3-day and 7-day ceftriaxone prophylaxis for cirrhotic patients with acuteconflicts of interest to declare.
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548 T.-H. Lee et al.esophageal variceal bleeding. There was also no difference in 28 day survival rate between
these two groups.
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Infection is commonly encountered in cirrhotic patients and
is associated with significant morbidities and mortality. The
infection rate was reported to be 32e66% in patients with
upper gastrointestinal bleeding.1,2 Therefore, in recent
times, prophylactic antibiotics have been routinely rec-
ommended for cirrhotic patients with upper gastrointes-
tinal bleeding.3e5 Esophagogastric variceal hemorrhage is
an important complication in cirrhotic patients character-
ized by high rebleeding rate and mortality.6 These patients
are particularly vulnerable to bacterial infections,7,8 and
such infections further result in increased rebleeding rates
and higher mortality in this group.9,10
Although prophylactic antibiotics have been recom-
mended for cirrhotic patients with upper gastrointestinal
bleeding, the regimen and duration of its use remain an
inconclusive issue.11,12 In recent times quinolones and third
generation cephalosporins, especially ceftriaxone, have
been more often used for prophyalxis.6,13 The duration for
antibiotic usage varies in the literature, ranging from 3 days
to 10 days.3,5 Prophylaxis use for 7 days was more often
used and recommended.4e6 In a survey of infections in
cirrhotic patients with upper gastrointestinal bleeding per-
formed by Bernard et al1, most infections occurred in the
first 5 days after admission and half within the first 48 hours.
Considering the cost-effectiveness and drug resistance is-
sues, the necessity for such prophylaxis for 7 days might
need to be reevaluated. Therefore, we designed this study
to investigate the duration of antibiotic prophylaxis for
cirrhotic patients with acute esophageal variceal bleeding.Methods
We enrolled patients suffering from acute esophageal var-
iceal bleeding documented by endoscopic examination and
they received endoscopic variceal ligation during this ses-
sion. The endoscopic variceal ligation was mostly per-
formed by experienced endoscopists or alternatively, by 2nd
year fellows supervised by experienced endoscopists. We
use a multiband ligator loaded with seven bands for liga-
tion. Those who had the following signs suggestive of
infection were excluded, including fever >37.5C, white
blood cell count >15000 mm3 or immature neutrophils
>500 mm3, polymorphonuclear cell count >250/mm3 in
ascitic fluid, >15 leukocyte count per high power filed in
urinalysis, and suspected pneumonia in chest x-rays.14
Endoscopy was performed within 24 hours after the
arrival to the emergency department. We excluded those
who had received antibiotics within 2 weeks, were
<18 years old, pregnant, allergic to ceftrioxone, or had
malignacy other than hepatocellular carcinoma.After receiving good explanations and giving their con-
sent, these patients were randomly allocated to two groups
and received prophylactic antibiotics after endoscopic ex-
amination; Group I: receiving ceftriaxone 500 mg (Roce-
phin, Roche, Kaiseraugst, Switzerland) intravenous bolus
stat and then every 12 hours for 3 days; and Group II:
receiving ceftriaxone 500 mg intravenous bolus stat and
then every 12 hours for 7 days. We used simple randomi-
zation to allocate these patients and drew names from an
envelope with a 1:1 ratio to allocate them to either Group I
or Group II. They all received intravenous glypressin 1 mg
every 6 hours for 3 days. They started to feed on the 2nd day
if not contraindicated. The second endoscopic treatment
for esophageal varices was performed, if planned by their
attending physician, 2 weeks later. We recorded the de-
mographic data, vital signs, comorbidity (including coronary
artery disease, heart failure, cerebrovascular accident,
chronic obstructive pulmonary disease, and uremia), pres-
ence of hepatocellular carcinoma or portal vein thrombosis;
checked hemogram, urinalysis, chest x-ray, ascites routine
(if apparent ascites existed), classification of variceal size,
and ChildePugh classification. We monitored the events of
rebleeding, infection, and transfusion amount after
enrollment. If there were new infection signs lasting
>24 hours in patients after enrollment and prophylactic
antibiotic use, they would be eliminated from this study.
Further treatment was decided by their attending physi-
cian. This study was approved by the Research Ethics Re-
view Committee of the Far Eastern Memorial Hospital and
was monitored during its execution (FEMH IRB 97086). It was
registered in Clinical Trial Registration: NCT00838864.
We used rebleeding rate within 14 days as the primary
end point. It is defined as the following events after initial
stabilization of vital signs for 24 hours: (1) recurrence of
hematemesis or bloody stool; and (2) tarry stool and need
of transfusion more than two units of blood, or with systolic
pressure <100 mmHg or pulse rate >100 per minute. The
secondary end points were survival rate within 28 days and
the amount of transfusion during admission.
All data were analyzed with the statistical software SPSS
version 20 (SPSS Inc., Chicago, IL, USA) for windows.
Regarding the baseline characteristics, the categorical data
were compared with Chi-square test or Fisher’s exact test.
The continuous data were compared with the Man-
neWhitney U-test. We used Fisher’s exact test to examine
the differences of rebleeding rate and survival rate within
28 days. ManneWhitney U-test was used to examine the
difference in transfusion amount during admission.
Results
From May 2009 to Jan 2013, there were 168 patients
screened for eligibility. Sixty-five patients did not give their
Antibiotic prophylaxis in variceal bleeding 549consent and 24 patients were excluded because of infection
signs. There were 79 patients enrolled; 40 were allocated
to Group I and 39 were allocated to Group II. Two patients
in Group I dropped out from this study, one because of
withdrawal of consent and one because of persistent fever;
six patients in Group II dropped out from this study, three
because of withdrawal of consent, two because of persis-
tent fever, and one because of pneumonia. There were 38
patients in Group I and 33 patients in Group II that
completed the study course and were available for analysis
(Figure 1). There were 35 male patients and 3 female pa-
tients in Group I with mean age of 54.7 years; there were 29
male patients and 4 female patients in Group II with a mean
age of 50.0 years. There were no difference for the age
(p Z 0.121) and gender (p Z 0.697) between these two
groups. For etiology of cirrhosis, there were 14 patients
with hepatitis B, 11 patients with hepatitis C, and 24 pa-
tients were alcoholic in Group I. There were 13 patients
with hepatitis B, 6 patients with hepatitis C, and 19 pa-
tients were alcoholic in Group II. There were no significant
differences in the mean number of comorbidities between
Group I (0.66  0.71) and Group II (0.42  0.50), pZ 0.185.Screening for eligibility 
Enrollment 
Randomization     
Allocation 
Dropped out
Consent withdrawal
     Persistent fever: 1 
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Figure 1 Patient participThere were also no significant differences between these
two groups for patients with hepatocellular carcinoma (10
in Group I, 6 in Group II, p Z 0.57), portal vein thrombosis
(one in Group I, two in Group II, pZ 0.594), and ascites (19
in both Group I and Group II, p Z 0.635).
The mean systolic blood pressure of the Group I was
122.84  26.12 mmHg, the mean heart rate was
96.55  20.73 beats per minutes; the mean systolic blood
pressure of the Group II was 123.33  21.58 mmHg, the
mean heart rate was 101.36  27.90 beats per minutes.
There were no differences for the systolic blood pressure
(pZ 0.751) and heart rate (pZ 0.381) between these two
groups. There were two patients (5.3%) in Group I and one
patient (3.0%) using aspirin and showed no difference
(p > 0.99). There was no patient using anticoagulant. In
Group I, the hemoglobin level was 9.82  2.02 g/dL, white
blood cell count was 7.11  2.50  103/mm3, platelet count
was 105.53  50.14  103/mm3, prothrombin time INR
(international normalized ratio) was 1.3  0.2; In Group II,
the hemoglobin level was 8.68  2.31 g/dL, white blood cell
count was 6.85  2.88  103/mm3, platelet count was
91.76  45.16  103/mm3, prothrombin time INR wasExcluded 
Signs of infection: 24 
No consent: 65 
 Randomization 
Dropped out
: 1   Consent withdrawal: 3 
   Persistent fever: 2 
Pneumonia: 1  
Group II: 39 
33 
ation and study course.
Table 2 Endoscopic findings of Group I and Group II.
Group I
(nZ 38)
Group II
(nZ 33)
p
Active bleeding 12 (32%) 12 (36%) 0.802
Variceal form 0.621
F1 2 (5%) 1 (3%)
F2 28 (74%) 22 (67%)
F3 8 (21%) 10 (30%)
Band number used 4.9  1.5 5.2  1.4 0.317
F1 Z Form 1; F2 Z From 2; F3 Z Form 3.
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significant for hemoglobin level (pZ 0.028), not significant
for white cell count (p Z 0.665) and platelet count
(p Z 0.343), and prothrombin time INR (p Z 0.300). In
Group I, the serum creatinine was 1.17  1.02 mg/dL, the
serum albumin was 3.18  0.56 g/dL, the ChildePugh
classification was A in 17 patients (45%), B in 19 patients
(50%), and C in two patients (5%); In Group II, the serum
creatinine was 0.78  0.39 mg/dL, the serum albumin was
2.99  0.474 g/dL, the ChildePugh classification was A in 10
patients (30%), B in 17 patients (52%), and C in six patients
(18%). The difference between these two groups was sig-
nificant for serum creatinine (pZ 0.049), not significant for
serum albumin (p Z 0.103), and ChildePugh classification
(p Z 0.155). The slightly higher mean creatinine level in
Group I rendered the baseline condition favoring Group II,
and the slightly lower mean hemoglobin level in Group II
rendered the baseline condition favoring Group I. Overall,
there was no significant difference at the baseline between
these two groups (Table 1). There was also no difference of
size of esophageal varices, frequency of active bleeding
(32% vs. 36%, p Z 0.802) during endoscopic examination
and mean band number used (4.9  1.5 vs. 5.2  1.4,
p Z 0.317) between these two groups (Table 2).Table 1 Baseline characteristics of Group I and Group II.
Group I
(n Z 38)
Group II
(nZ 33)
p
Male (%) 35 (92%) 29 (88%) 0.697
Age 54.71  12.39 49.97  8.81 0.121
Systolic BP (mmHg) 122.84  26.12 123.33  21.58 0.751
Heart rate 96.55  20.73 101.36  27.90 0.381
Shock 2 (5%) 0 (0%) 0.495
Etiology of HBV 14 (37%) 13 (39%) >0.99
Etiology of HCV 11 (29%) 6 (18%) 0.404
Etiology of alcohol 24 (63%) 19 (58%) 0.808
Comorbidity
number
0.66  0.71 0.42  0.50 0.185
Use of antiplatelet 2 (5.3%) 1 (3.0%) >0.99
HCC 10 (26%) 6 (18%) 0.570
PVT 1 (3%) 2 (6%) 0.594
Ascites 19 (50%) 19 (58%) 0.635
Hemoglobin (g/dL) 9.82  2.02 8.68  2.31 0.028*
WBC (1000/mm3) 7.11  2.50 6.85  2.88 0.665
Platelet
(1000/mm3)
105.53  50.14 91.76  45.16 0.343
Prothrombin
time INR
1.3  0.2 1.3  0.3 0.300
Creatinine (mg/dL) 1.17  1.02 0.78  0.39 0.049*
Albumin (g/dL) 3.18  0.56 2.99  0.474 0.103
ChildePugh
classification
0.155
A 17 (45%) 10 (30%)
B 19 (50%) 17 (52%)
C 2 (5%) 6 (18%)
BP Z blood pressure; HBV Z hepatitis B virus;
HCC Z hepatocellular carcinoma; HCV Z hepatitis C virus;
INR Z international normalized ratio; PVT Z portal vein
thrombosis; WBC Z white blood cell.
* Z with significance.There were both three patients in Group I (8%) and in
Group II (9%) who developed rebleeding within 14 days. The
mean transfusion amount was 2.71  2.84 units in Group I
and 3.18  4.07 units in Group II. No patient in Group I and
one patient in Group II died within 28 days. There were no
differences between Group I and Group II for rebleeding
rate (p > 0.99), transfusion amount (pZ 0.839), and 28 day
survival (pZ 0.465) (Table 3). Of the two patients in Group I
and six patients in Group II that dropped out from the study,
none developed rebleeding episodes or died within 28 days
of their initial enrollment. We performed multiple logistic
regression to analyze the risk factors for rebleeding, and
only found shock on admission to be an independent factor
for rebleeding (p Z 0.022). All other factors were not sig-
nificant. Almost half of the study patients did not regularly
attend our outpatient clinic several months later, therefore
we do not have long term follow up data for analysis.
Discussion
Acute variceal bleeding is a serious complication in
cirrhotic patients and used to be associated with very high
mortality rates. However, the mortality rate decreased
markedly over the past two decades, probably mainly
because of the application of vasoactive agent, endoscopic
therapy, and antibiotic prophylaxis.6,15 The clinical out-
comes of cirrhotic patients with chronic viral infections are
further improved by active treatment of underlying viral
hepatitis.16 The in-hospital mortality rate was even re-
ported to reach 0 in ChildePugh Class A and B cirrhotic
patients in 2000.15 Our present study also showed a low
mortality in patients with acute esophageal variceal
bleeding and only one out of these 71 patients died within
28 days of enrollment. Besides prophylaxis with ceftriax-
one, all of our patients received intravenous glypressin and
endoscopic variceal ligation. Most of these patients
belonged to ChildePugh Classes A and B (95% in Group I andTable 3 The outcomes of Group I and Group II.
Outcome
evaluations
Group I
(nZ 38)
Group II
(nZ 33)
p
Rebleeding 3 (8%) 3 (9%) >0.99
Transfusion amount
(PRBC þ WB)
2.71  2.84 U 3.18  4.07 U 0.839
Survived after
28 days
38 (100%) 32 (97%) 0.465
PRBC Z packed red blood cell; U Z units; WB Z whole blood.
Antibiotic prophylaxis in variceal bleeding 55182% in Group II). These factors might contribute to the
relatively good survival rates in the patients of our study.
Bacterial infections are frequent complications in pa-
tients with cirrhosis, with an incidence of w32% on and
during admission.7 These patients are predisposed to infec-
tion due to impaired immune function, increased passage of
bacteria from the gut (bacterial translocation), and bacte-
rial overgrowth.17 The immune dysfunction in cirrhotic pa-
tients is multifactorial and is probably due to a decrease in
bactericidal activity of phagocytic cells, complement level,
and impaired function of the reticuloendothelial system
which is caused mainly by portosystemic shunting and
impaired Kupffer’s cell phagocytic activity.17 Bacterial
translocation refers to migration of bacteria or bacterial
products from the lumen of intestines to extraintestinal
sites. Several mechanisms contribute to bacterial trans-
location in cirrhotic patients, including intestinal bacterial
overgrowth, intestinal motility disturbances, decreased im-
munity, and impaired intestinal barrier function, as re-
flected by increased intestinal permeability.17,18 During
hemorrhage, the barrier function of the gastrointestinal
tract might be impaired and the intestinal permeability
could be increased. Kim et al18 reported that increased in-
testinal permeability is a predictor of bacterial infection in
patients with decompensated liver cirrhosis and hemor-
rhage. Moreover, endoscopic treatment with band ligation is
reported to be associated with 8.8% of bacteremia. Consid-
ering the development of mucosal defects following variceal
ligation, the true frequency of bacteremiamight be higher.19
Prophylactic antibiotics have been routinely recom-
mended for cirrhotic patients with upper gastrointestinal
bleeding in recent years.3e6,20 Several studies have re-
ported that antibiotic prophylaxis could reduce the
rebleeding rate in cirrhotic patients with acute variceal
hemorrhage.8,21,22 Quinolones and third generation cepha-
losporins have been more often reported for prophylaxis,
including oral norfloxacin, intravenous ciprofloxacin, and
ceftiraxone.8,14,21e23 Intravenous ceftriaxone is preferred
for prophylaxis in patients with more severe liver dis-
ease.6,13,14,24 Wu et al25 reported that intravenous cefazo-
lin could achieve similar prophylactic effects for acute
variceal hemorrhage compared with ceftriaxone in Child-
ePugh Class A patients.
Short term prophylactic antibiotics have been recom-
mended for cirrhotic patients with variceal hemorrhage.6,26
The duration for prophylactic antibiotic use was variable in
the literature, ranging from 3 to 10 days, and 7 days was
more often used and recommended.3e6,11 However, in this
survey of infections in cirrhotic patients with upper
gastrointestinal bleeding performed by Bernard et al,1 most
infections occurred in the first 5 days after admission and
half within the first 48 hours. Bleichner et al27 reported 32
(22%) out of 149 patients admitted to the intensive care
unit had shown infection within 48 hours of admission. In
our small scale study, there were three patients in Group I
(8%) and in Group II (9%) who developed rebleeding within
14 days, and no significant difference was found. There was
also no difference in the 28-day mortality between these
two groups. Another issue is when to start antibiotic pro-
phylaxis. Brown et al28 reported antibiotics administrated
up to 8 hours following endoscopy were associated with
improved survival at 28 day in variceal hemorrhage.There are several limitations in the current study. The
case number is relatively small to draw a strong conclusion.
It was carried out in only one hospital and the studied re-
sults might not generalize for all other practice appropri-
ately. More than half of the invited candidates initially
were excluded due to signs of infection and lack of consent,
and they were likely to have more severe diseases. Those
who were enrolled were in a relatively more stable condi-
tion. Therefore, our results might not be applicable to
patients with more severe liver disease and variceal
bleeding. Further large scale studies, maybe in a multi-
center design, are warranted to validate our results.
In conclusion, our small scale study demonstrated that
there was no difference in the rebleeding rate between 3-
day and 7-day ceftriaxone prophylaxis for cirrhotic pa-
tients with acute esophageal variceal bleeding. There was
also no difference in 28- day mortality between these two
groups.Acknowledgments
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